Work

Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.7527

Authors: Matthew Steven Davids, Andrew Warwick Roberts, John Francis Seymour, John F. Gerecitano, Brad S. Kahl, Thomas J. Kipps, John M. Pagel, Soham D. Puvvada, Lori A. Gressick, Ming Zhu, Martin Dunbar, Brenda Chyla, Maria E. Verdugo, Su Young Kim, William G. Wierda

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Moores Cancer Center, Swedish Medical Center, University of Arizona, AbbVie (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2762535272

Cites:

Cited by: 13

Related to: 10